In 2020, Yu et al. (2020) employed WES and examined 299 diagnostic and 73 relapse samples from 372 ALL patients to assess the incidence of FPGS mutations, as well as those in two crucial thiopurine pathway genes, NT5C2 and PRPS1 which have been previously demonstrated to be important mechanisms for resistance in leukemia (Schroeder et al., 2019). Here, FPGS is linked to acute lymphoblastic leukemia.